Caris Life Sciences Reports Q3 2026 Financial Results
Caris Life Sciences announced its third-quarter 2026 financial results, reporting revenue of $275.4 million and earnings per share of $0.05, both exceeding analyst expectations.
Stocks · News reference
TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $38
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Caris Life Sciences Q3 EPS $0.05 Beats $0.04 Estimate, Sales $275.358M Beat $255.363M Estimate
8-K filing — Caris Life Sciences, Inc. (CAI)
Filed: 2026-11-04 AccNo: 0002019410-26-000067 Size: 440 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Deutsche Bank Research Adjusts Price Target for CA Immo
Deutsche Bank Research has lowered its price target for CA Immo shares from 23.00 EUR to 22.00 EUR while maintaining a 'Hold' rating.
Erste Group Downgrades CA Immo to Hold
Erste Group has downgraded its rating for CA Immo to 'Hold' and reduced its price target to 23.6 Euro.
BTIG Maintains Buy Rating and Raises Price Target for Caris Life Sciences
BTIG analyst Mark Massaro has reaffirmed a "Buy" rating on Caris Life Sciences and increased the price target from $33 to $38.